Grail shares rise 17.24% after hours as Q3 revenue jumps 26% and Canaccord raises price target to $105.

Grail Inc. surged 17.24% in after-hours trading, driven by a 26% year-over-year revenue increase in Q3 2025, fueled by 28% growth in U.S. Galleri revenue, and a raised price target of $105 from Canaccord Genuity. The company also announced a $300 million at-the-market stock offering and a strategic partnership with Samsung to expand its multi-cancer early detection test in Asia. These developments underscored investor confidence in Grail’s market potential, despite ongoing losses, as improved non-GAAP gross margins and clinical validation bolstered optimism. The stock’s rally aligned with its 52-week high and reinforced its position as a high-growth biotech play.